{"id":"NCT02447432","sponsor":"GlaxoSmithKline","briefTitle":"A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants","officialTitle":"Study to Compare Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-06-11","primaryCompletion":"2016-01-23","completion":"2016-05-22","firstPosted":"2015-05-18","resultsPosted":"2017-03-16","lastUpdate":"2018-08-02"},"enrollment":320,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Streptococcal"],"interventions":[{"type":"BIOLOGICAL","name":"Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (4-dose presentation)","otherNames":["10Pn","10PN-PD-DiT","GSK Biologicals' 10-valent pneumococcal polysaccharide and non-typeable Haemophilus influenzae protein D conjugate GSK1024850A (10Pn-PD-DiT)"]},{"type":"BIOLOGICAL","name":"Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (1-dose presentation)","otherNames":["Synflorix™","GSK Biologicals' 10-valent pneumococcal polysaccharide and non-typeable Haemophilus influenzae protein D conjugate GSK1024850A (10Pn-PD-DiT) vaccine"]},{"type":"BIOLOGICAL","name":"DTPw-HBV/Hib","otherNames":["GSK Biologicals' diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type b vaccine"]}],"arms":[{"label":"10Pn_4d Group","type":"EXPERIMENTAL"},{"label":"10Pn Group","type":"ACTIVE_COMPARATOR"}],"summary":"The primary aim of the study is to demonstrate that an investigational 4-dose presentation of the 10Pn-PD-DiT vaccine with preservative is non-inferior to the licensed presentation of Synflorix (preservative-free) in terms of immune responses to the 10 vaccine pneumococcal serotypes (primary objective) and to the vaccine-related pneumococcal serotype 19A (first secondary objective), after administration of a 3-dose primary vaccination course at 6, 10 and 18 weeks of age co-administered with the first 2 doses of DTPw-HBV/Hib vaccine given at 6, 10 and 14 weeks of age (according to the Expanded Program on Immunization (EPI) schedule).\n\nIn addition, the study will also assess the safety, reactogenicity, immunogenicity and antibody persistence (approximately 7 months following primary vaccination) of the 4-dose presentation of the 10Pn-PD-DiT vaccine given as primary vaccination schedule at 6, 10 and 18 weeks of age followed by a booster dose at 38 weeks.\n\nThis study also aims at assessing the safety, reactogenicity and immunogenicity of the 4-dose presentation of the 10Pn-PD-DiT vaccine when given as a booster dose at approximately 9 months of age.","primaryOutcome":{"measure":"Antibody Concentrations Against Pneumococcal Serotypes (Epoch 001)","timeFrame":"At study Month 4, e. g. at one month post-Dose 3 of pneumococcal vaccine","effectByArm":[{"arm":"10Pn_4d Group","deltaMin":2.78,"sd":null},{"arm":"Synflorix Group","deltaMin":3.03,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"42 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":18},"locations":{"siteCount":1,"countries":["Bangladesh"]},"refs":{"pmids":["29277353"],"seeAlso":["https://clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":160},"commonTop":["Pain","Swelling","Irritability","Decreased appetite","Pyrexia"]}}